The POLO trial provided a milestone in targeted therapy of PDAC albeit tailored to a minimal subgroup of around 3–6% of germline BRCA1/2-mutated patients with pancreatic cancer [7,29]. Here, BRCA1 is linked to familial pancreatic carcinoma.